117 related articles for article (PubMed ID: 16008658)
41. Interferon beta-1A: new preparation. A short-term impact on the course of multiple sclerosis.
Prescrire Int; 1998 Oct; 7(37):142-3. PubMed ID: 10915418
[TBL] [Abstract][Full Text] [Related]
42. [Skin necrosis induced by heparin: apropos of 2 cases].
Andolfatto S; Latger-Cannard V; Maistre ED; Briquel ME; André E; Montange F; Reichert S; Lecompte T
Ann Biol Clin (Paris); 2001; 59(5):651-4. PubMed ID: 11602401
[No Abstract] [Full Text] [Related]
43. Calcified subcutaneous nodules: a long-term complication of interferon beta-1a therapy.
Macbeth AE; Kendall BR; Smith A; Saldanha G; Harman KE
Br J Dermatol; 2007 Sep; 157(3):624-5. PubMed ID: 17596164
[No Abstract] [Full Text] [Related]
44. [Therapy of multiple sclerosis with interferon-beta-1b. Educating the patient and managing side-effects].
Walther EU; Dietrich E; Hohlfeld R
Nervenarzt; 1996 Jun; 67(6):452-6. PubMed ID: 8767199
[TBL] [Abstract][Full Text] [Related]
45. [Skin reactions to interferon alpha in a series of 92 patients with multiple sclerosis].
Fortuño Y; Marcoval J; Gallego I; Moreno A; Arbizu T; Peyrí J
Med Clin (Barc); 1999 Oct; 113(12):447-8. PubMed ID: 10570511
[TBL] [Abstract][Full Text] [Related]
46. Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial.
Comi G; De Stefano N; Freedman MS; Barkhof F; Polman CH; Uitdehaag BM; Casset-Semanaz F; Hennessy B; Moraga MS; Rocak S; Stubinski B; Kappos L
Lancet Neurol; 2012 Jan; 11(1):33-41. PubMed ID: 22146409
[TBL] [Abstract][Full Text] [Related]
47. [Interferon-β1b in multiple sclerosis therapy: more than 20 years clinical experience].
Hartung HP; Haas J; Meergans M; Tracik F; Ortler S
Nervenarzt; 2013 Jun; 84(6):679-704. PubMed ID: 23669866
[TBL] [Abstract][Full Text] [Related]
48. A case of septal panniculitis secondary to interferon treatment.
Ozuguz P; Kacar SD; Karaca S; Tokyol C
Cutan Ocul Toxicol; 2014 Dec; 33(4):351-2. PubMed ID: 24641120
[TBL] [Abstract][Full Text] [Related]
49. Cutaneous reactions following subcutaneous beta-interferon-1b injection.
Ohata U; Hara H; Yoshitake M; Terui T
J Dermatol; 2010 Feb; 37(2):179-81. PubMed ID: 20175855
[No Abstract] [Full Text] [Related]
50. Lethal capillary leak syndrome after a single administration of interferon beta-1b.
Niederwieser G
Neurology; 2000 Apr; 54(7):1545-6. PubMed ID: 10751284
[No Abstract] [Full Text] [Related]
51. Vitiligo and multiple sclerosis in a patient treated with interferon beta-1a: a case report.
Kocer B; Nazliel B; Oztas M; Batur HZ
Eur J Neurol; 2009 Apr; 16(4):e78-9. PubMed ID: 19222549
[No Abstract] [Full Text] [Related]
52. [Heparin-induced thrombopenia and thrombosis].
Stöckli TC; Walther A; Görres G; Ritz R; Marbet GA
Schweiz Med Wochenschr; 1996 Mar; 126(12):483-8. PubMed ID: 8650513
[TBL] [Abstract][Full Text] [Related]
53. [Interferon beta-1b retinopathy during a treatment for multiple sclerosis].
Sommer S; Sablon JC; Zaoui M; Rozot P; Hosni A
J Fr Ophtalmol; 2001 May; 24(5):509-12. PubMed ID: 11397988
[TBL] [Abstract][Full Text] [Related]
54. Ardeparin and danaparoid for prevention of deep vein thrombosis.
Med Lett Drugs Ther; 1997 Oct; 39(1011):94-5. PubMed ID: 9379998
[No Abstract] [Full Text] [Related]
55. Different responses to interferon beta-1b treatment in patients with neuromyelitis optica and multiple sclerosis.
Uzawa A; Mori M; Hayakawa S; Masuda S; Kuwabara S
Eur J Neurol; 2010 May; 17(5):672-6. PubMed ID: 20039942
[TBL] [Abstract][Full Text] [Related]
56. Development of myasthenia gravis in two patients with multiple sclerosis following interferon beta treatment.
Dionisiotis J; Zoukos Y; Thomaides T
J Neurol Neurosurg Psychiatry; 2004 Jul; 75(7):1079. PubMed ID: 15201386
[No Abstract] [Full Text] [Related]
57. Interferon beta-1b and secondary progressive multiple sclerosis: licence extension. Useful, but further assessment required.
Prescrire Int; 2000 Aug; 9(48):110-1. PubMed ID: 11067719
[TBL] [Abstract][Full Text] [Related]
58. Glatiramer acetate in treatment-naïve and prior interferon-beta-1b-treated multiple sclerosis patients.
Zwibel HL;
Acta Neurol Scand; 2006 Jun; 113(6):378-86. PubMed ID: 16674604
[TBL] [Abstract][Full Text] [Related]
59. Comparison of injection site pain and injection site reactions in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a or 1b.
Baum K; O'Leary C; Coret Ferrer F; Klímová E; Procházková L; Bugge J;
Mult Scler; 2007 Nov; 13(9):1153-60. PubMed ID: 17967843
[TBL] [Abstract][Full Text] [Related]
60. [Subacute cutaneous lupus erythematosus and interferon beta-1 a].
Schmutz J; Barbaud A; Tréchot P
Ann Dermatol Venereol; 2000 Feb; 127(2):237. PubMed ID: 10739993
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
